44results about "Urinary tract/kidney cells" patented technology

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

The application discloses a DNA molecule for promoting mRNA expression, and a 3'UTR in an mRNA molecule obtained by transcription according to the DNA molecule, wherein the DNA molecule is derived from COX5A, COX17 or COX7B of a cytochrome C oxidase family of human origin. The application also discloses application of a composition containing the 3'UTR in preparation of an RNA therapeutic drug or an mRNA vaccine. Compared with a control group alpha-globin, insertion of the 3'UTR fragment provided by the application increases the expression of sea renilla luciferase in Lenti-X 293T cells by 2.03-2.88 times, and increases the expression of sea renilla luciferase in HeLa cells by 3.62-6.69 times, which shows excellent prospects of the 3'UTR in application in the RNA therapeutic drug or the mRNA vaccine.

Methods for identifying enriched heterogeneous renal cell populations with therapeutic potential, the enriched heterogeneous renal cell populations with therapeutic potential, and their uses. In some embodiments, it includes a method for identifying enriched heterogeneous renal cell populations as having therapeutic potential. In this method, it is determined whether the cells of the enriched heterogeneous renal cell population express at least one of: (i) ureteral bud and / or cap mesenchymal (UB / CM) markers; and / or (ii) podocyte markers.

The present disclosure relates to methods, compositions, and systems for detecting whether a subject exposed to a coronavirus has developed a neutralizing antibody response. Also disclosed are methods for determining whether a patient infected by a coronavirus is likely to respond to treatment with an antibody preparation. Also disclosed are methods for detecting the level of neutralizing antibody response in a sample of serum from a subject exposed to a coronavirus or to a coronavirus vaccine.

An object of the present invention is to provide a method for improving a proportion of capsids containing a gene of interest GOI in a method for producing a virus, and to provide a method for improving a proportion of capsids containing a gene of interest GOI in a method for introducing a nucleic acid into cells, the method including a nucleic acid introduction step of adding a nucleic acid to a suspension containing cells. According to the present invention, there is provided a method for producing a virus, the method including a nucleic acid introduction step of adding a nucleic acid to a suspension containing cells having a density of 10×106 cells / mL or more, and a culture step of culturing the cells into which the nucleic acid has been introduced, in which the nucleic acid is added in a case where a population cell doubling time of the suspension satisfies 35.4 hours or less.

The application discloses a mutant Cas12i nuclease and application thereof, and belongs to the technical field of gene editing. The Cas mutant protein provided by the application is a mutant protein in which the 7th, 168th, 273rd, 332nd, 478th, 505th and 551st amino acids of SEQ ID NO:1 are all mutated into arginine, and other amino acid sequences remain unchanged. The application improves the editing efficiency by mutating multiple amino acids of the wild-type Cas12i protein, and can be used for multi-gene editing.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

This invention discloses a bispecific nanobody targeting CXCL1 and PD-L1 and its applications, belonging to the fields of antibody engineering and bioengineering technology. The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing CXCL1 and one nanobody recognizing PD-L1, with the nanobody monomers linked by a linker. The bispecific nanobody targeting PD-L1 / CXCL1 provided by this invention has a unique structure, enabling it to specifically recognize and bind to both CXCL1 and PD-L1. It achieves an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, effectively preventing immune escape-induced resistance to antibody therapy, making it suitable for a wider range of patients, and providing a new approach for CRC treatment.

Provided is a method for storing or transporting renal cells that have a high cell viability, maintain a physiological function of the kidney, and can be used as a drug evaluation system, at a temperature lower than a culture temperature. An aspect of the present invention is a method for storing or transporting renal cells, the method including a maintenance step of managing a liquid containing aggregates of the renal cells to a temperature that is a maintenance temperature and lower than a culture temperature of the renal cells and at which the liquid is not frozen.

The present invention provides methods to identify and quantify empty, partial and full capsids. The capsids can be purified from a crude AAV sample using affinity chromatography and eluted from the solid support. The purified capsids can then be subjected to density gradient equilibrium analytical ultracentrifugation (DGE-AUC) for characterization and quantitation of capsid content.

The application provides an anti-LC-1 antibody or antigen binding fragment thereof, a preparation method and application, and relates to the technical field of biotechnology.The anti-LC-1 antibody or antigen binding fragment thereof contains a complementarity determining region of a heavy chain variable region and a complementarity determining region of a light chain variable region, the complementarity determining region of the heavy chain variable region includes an amino acid sequence identical to VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO.1; the complementarity determining region of the light chain variable region includes an amino acid sequence identical to VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO.2.The anti-LC-1 antibody or antigen binding fragment thereof has good specific binding capacity with the LC-1 antigen, and can be used for identification of the anti-LC-1 antibody or the LC-1 antigen, and auxiliary diagnosis and detection of diseases positive to the anti-LC-1 antibody.

This invention provides a human embryonic kidney (HEK) cell line or its progeny, wherein the cell line is deposited with accession numbers selected from CCTCC NO: C202372, CCTCC NO: C2023129, CCTCC NO: C2023130, CCTCC NO: C2023131, CCTCC NO: C2023132, CCTCC NO: C2023133, and CCTCC NO: C2023134. This invention also provides a method for preparing rAAV using the said cell line or its progeny, or a kit for preparing rAAV containing the said cell line or its progeny.

To provide a cell preparation method, particularly a method, an inducer, and a kit for converting differentiated somatic cells into other somatic cells without gene transfer.SOLUTION: Provided is a method for preparing somatic cells characterized in that differentiated somatic cells of a mammal are cultured in a medium for inducing differentiation of somatic cells other than the differentiated somatic cells in the presence of a TGF-β pathway inhibitor, thereby converting the differentiated somatic cells into other somatic cells.SELECTED DRAWING: None

This invention belongs to the field of medicine, specifically disclosing a drug-loaded biomimetic nanodecoy based on genetic engineering, its preparation method, and its application. The drug-loaded biomimetic nanodecoy of this invention comprises CCR2-overexpressing nanovesicles, and the hydrophobic regions of the nanovesicles are loaded with curcumin. This invention also provides a method for preparing the drug-loaded biomimetic nanodecoy based on genetic engineering and its application. The overexpressed CCR2 is used to adsorb excess CCL2 to inhibit the binding of macrophages to CCL2, preventing macrophage chemotaxis and subsequent TGF-β production. This inhibits the activation of hepatic stellate cells by removing pro-fibrotic mediators upstream; simultaneously, curcumin is released to block the downstream TGF-β / Smad signaling pathway, thereby inhibiting the activation of hepatic stellate cells.

Provided herein are systems and methods for the production of gene therapy products. The system may comprise a reactor vessel housing a fixed-bed substrate for cell growth, a recirculation mixing vessel connected to the reactor vessel via a closed-loop recirculation path, and a pump regulating the recirculation rate between the two vessels. The methods and systems provided herein provide a controlled environment for efficient production of gene therapy products, enhancing the scalability and reproducibility of the manufacturing process.

The present invention relates to novel interleukin-2 (IL-2) muteins. The present invention further provides fusion proteins and immunoconjugates containing the IL-2 muteins, as well as nucleic acids encoding the IL-2 muteins, vectors containing the nucleic acids, and host cells. The present invention also provides methods for preparing the IL-2 muteins, pharmaceutical compositions containing the IL-2 muteins, and therapeutic uses of the muteins.

This invention relates to a HEK-293 cell line that grows under animal component-free suspension conditions. This invention further relates a HEK-293 cell line that grows under adherent conditions. The cell lines may provide rapid and scalable production of adenoassociated virus (AAV) and support production of all serotypes and chimera of AAV.

Methods for identifying enriched heterogeneous renal cell populations with therapeutic potential, enriched heterogeneous renal cell populations with therapeutic potential, and uses thereof.

Methods for producing, culturing, and maintaining modified podocyte-like cells are disclosed herein. These methods include growing glomerular cells under in vitro conditions to differentiate them into podocyte-like cells. Kits comprising isolated and purified podocyte-like cells and culture media used for differentiating modified podocyte-like cells and / or podocyte-like cells are also disclosed herein. Modified podocyte-like cells can be used for recellularization of decellularized extracellular matrix. In some cases, recellularized isolated organs containing modified podocyte-like cells are disclosed herein.

The present invention provides a virus-like particle (VLP) having a viral envelope which comprises: (i) a membrane protein comprising the extracellular domain of CD86; and (ii) a CD3-binding membrane protein. The VLP may be used to activate T cells prior to viral transduction.

The application discloses a UCH-L1 specific antibody and application thereof in an auxiliary diagnosis kit for traumatic brain injury, and belongs to the technical field of immune analysis. The application provides an antibody targeting UCH-L1 and a chemiluminescence kit for detecting UCH-L1. The antibody provided by the application has high affinity, high sensitivity and a significantly shortened production cycle, and is more suitable for being applied to the field of in-vitro diagnosis reagents as a core raw material. The kit disclosed by the application can be used for the auxiliary diagnosis of diseases related to UCH-L1, such as traumatic brain injury.

Provided are an FLNB gene-knockout MDCK cell line, a construction method therefor and the use thereof. The FLNB gene-knockout cell line is named MDCK-FLNB-KO, and has been deposited in China Center for Type Culture Collection (CCTCC) on November 20, 2024, and the accession number is CCTCC NO: C2024391. The FLNB gene knockout uses CRISPR / Cas9 technology, wherein a sgRNA is designed for exon 1 of the FLNB gene of MDCK cells, an FLNB gene knockout vector plasmid 1 and plasmid 2 are constructed, and the plasmid 1 and the plasmid 2 are transfected into the MDCK cells to obtain the FLNB gene-knockout MDCK cell line. Compared with the original MDCK cell line, the obtained cell line has a lower adhesion ability and a higher yield when applied to influenza virus culture.

The present disclosure relates to methods of producing an enveloped virus in a suspension cell culture, the method comprising culturing a suspension cell line expressing a tetracycline-suppressible gene expression system in a cell culture medium. The present disclosure also relates to stable producer cell clones capable of producing an enveloped virus in a suspension cell culture.

The present disclosure relates to a method for producing an enveloped virus in a suspension cell culture, which includes culturing a suspension cell line expressing a tetracycline-repressible gene expression system in a cell culture medium. The present disclosure also relates to a stable production cell clone capable of producing an enveloped virus in a suspension cell culture.

The application relates to the technical field of shrimp molecular immunology, and in particular to an anti-Chinese shrimp hemocyanin monoclonal antibody and application. The anti-Chinese shrimp hemocyanin monoclonal antibody is anti-SHC-5C8, which can be expressed by recombinant Expi293 cells containing a recombinant plasmid pcDNA3.1 of the anti-Chinese shrimp hemocyanin monoclonal antibody gene. The anti-Chinese shrimp hemocyanin monoclonal antibody has good specificity, can be specifically combined with two subunits with molecular weights of 73kDa and 75kDa of Chinese shrimp hemocyanin, and can be applied as a positive internal reference for detecting the content of the anti-Chinese shrimp hemocyanin monoclonal antibody in animals immunized with Chinese shrimp hemocyanin.

A method for treating muscle-wasting diseases, such as spinal muscular atrophy or muscular dystrophy, using matrix-bound vesicles (MBVs) is disclosed. A composition for use in treating muscle-wasting diseases is also disclosed. This composition is a) exogenous matrix-bound nanovesicles (MBVs) derived from the extracellular matrix, wherein the MBVs do not express CD63 and CD81, or CD63 lo CD81 lo The MBV comprises: a) exogenous MBV derived from the extracellular matrix that does not contain alkaline phosphatase; b) bone marrow progenitor cells or bone marrow-derived cells treated with the exogenous MBV; and / or c) an effective amount of conditioned medium or a fraction thereof obtained from macrophages cultured in the presence of the exogenous MBV.

The application provides a PCNA binding protein, a preparation method and application, and relates to the technical field of biology. The PCNA binding protein contains a complementarity determining region of a heavy chain variable region and a complementarity determining region of a light chain variable region, the complementarity determining region of the heavy chain variable region comprises an amino acid sequence identical to VH-CDR1, VH-CDR2 and VH-CDR3 of the heavy chain variable region shown in SEQ ID NO. 1, and the complementarity determining region of the light chain variable region comprises an amino acid sequence identical to VL-CDR1, VL-CDR2 and VL-CDR3 of the light chain variable region shown in SEQ ID NO. 2. The binding protein has good specific binding capacity with PCNA, and can be used for identification of PCNA antibodies or PCNA antigens, and auxiliary diagnosis and detection of PCNA antibody positive diseases.

This specification describes a method for treating kidney disease, comprising administering a cell-derived product to the patient's perirenal adipose tissue (PRAT) in patients requiring treatment for kidney disease. Optionally, the cell-derived product is a plurality of mesenchymal stromal cells. Other diseases, including liver disease, cardiovascular disease, inflammatory disease, fibrous disease, autoimmune disease, and visceral disease, can be treated using this method.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides the a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

Provided is a production method for renal collecting duct cells, said method including a step for culturing ureteric bud cells or cells that have differentiated from ureteric bud cells in a culture medium that includes a TGFβ inhibitor, a Wnt inhibitor, and a phosphodiesterase inhibitor. Also provided is a production method for a renal collecting duct cell–containing organoid, said method including a step for culturing a ureteric bud organoid or an organoid that has differentiated from a ureteric bud organoid in a culture medium that includes a TGFβ inhibitor, a Wnt inhibitor, and a phosphodiesterase inhibitor.